Drug intelligence / Profile preview

SBRX22

Development stage: Preclinical
Lead developer: Stramsen Biotech
Modality: Small Molecules

Overview

SBRX22 is a plant-based drug candidate being developed by Stramsen Biotech Inc. for the treatment of pain associated with ovulation disorders in women. Developed using the company's proprietary database of medicinal plants, SBRX22 is part of the SBRX series of natural therapeutics. The drug is intended to provide a natural alternative for managing gynecological pain related to ovulatory dysfunction. While it is part of a pipeline that includes candidates in early-stage clinical trials, specific molecular targets and the active botanical ingredients of SBRX22 have not been publicly disclosed.

Beyond the preview

Go deeper on SBRX22.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBRX22.

Explore the full profile